Bionter AG is on a mission to revolutionise the analytical testing of subvisible particles in the biopharmaceutical industry. New York-based Dynamk Capital has led the startup’s seed round to grow the team and accelerate the market launch of its first product, scheduled next month.
Headquartered in Riehen, Basel Stadt, Bionter is driving patient safety, cost efficiency and sustainability through disruptive innovations in particle testing that increase the quality of drug product testing.
Bionter`s first product is a fully automated particle counter based on a new combination of light obscuration technology and smart automation to enable non-destructive sample testing. It is supported with single-use consumables, maintenance and training, applicable for biotech’s drug product sector.
To this day, players in the biopharmaceutical industry are confronted with how to minimise the number of costly samples required to determine particle count. Bionter’s device reduces the sample volume required, saving material for other analytical endpoints and reducing costs. The smart, automated workflow drives efficiency and minimises human interaction, hence improving reliability, data integrity, and patient safety. The particle counter is also compliant with current USP/EP/JP regulations familiar with manufacturers.
“Bionter technology is a game-changer in subvisible particle counting, one of the most important quality attributes of administered liquid biologics,” said Reinhard Vogt, chair of the Board of Bionter and Venture Partner at Dynamk Capital”
The company has completed the development of its patented technology and will launch it end of May 2022. The newly secured funds will support the go-to-market plans, enable the startup to expand its team and fuel its pipeline with new innovative developments.
Dynamk Capital, a growth equity and venture capital firm focused on life sciences, led the investment round. “We are thrilled to have Dynamk Capital join our team. They provide a wealth of experience growing life science tools companies and help position Bionter and help us make our vision a reality,” said Tobias Werk, CEO of Bionter. Werk is an expert in Pharmaceutical Sciences, with experience gained through his career at pharma giant Roche and Actelion/Idorsia.
(Press release/RAN)
Please login or sign up to comment.
Commenting guidelines